

BY REGISTERED POST AND BY EMAIL

Attn: Mr K. Anuraag Reddy & Mr S. Gopi Krishnan Arene Life Sciences Private Limited S.R. Chambers, #3-58, Ramachandrapuram, Sangareddy District, Telangana, INDIA

<u>Email</u>: anuraag@arenelife.com; gopi@arenelife.com <u>Copy</u>: info@arenelife.com; marketing@arenelife.com

23 June 2025

Notice of Intention to Terminate Licence Agreements

Dear Messrs Reddy & Krishnan

We refer to the following agreements between the Medicines Patent Pool Foundation (MPP) and Arene Life Sciences Private Limited (Arene):

- the agreement dated 9 April 2018, to which Gilead Sciences Inc. is also a party, except to the extent that the agreement has already been partially terminated by Arene in relation to tenofovir alafenamide (**Gilead Licence**);
- the agreement dated 3 September 2021 relating to glecaprevir and pibrentasvir (G/P Licence); and
- the agreement dated 3 January 2022 relating to molnupiravir (MOL Licence),

as amended from time to time (collectively, the Agreements).

Since February 2024, Arene has failed to communicate with MPP regarding the Agreements and has been non-responsive to all of our communications concerning the same. Arene is in breach of several provisions of the Agreements including, but not limited to:

- Sections 4.3, 5.2, and 6.3 of the Gilead Licence;
- Sections 3.4 (in part), 3.5, and 9.2 of the G/P Licence; and
- Sections 3.3, 3.4, and 3.5 of the MOL Licence.

MPP is entitled to terminate the G/P Licence and MOL Licence with immediate effect. MPP is also entitled to terminate the Gilead Licence upon 30 days' written notice if Arene fails to cure its material breaches within that period. 2

Please accept this letter as formal notice that, without any further written notice and unless MPP communicates otherwise in writing in the intervening period, the Agreements will terminate on 31 July 2025.

² Gilead Licence, Section 10.2.

¹ G/P Licence, Section 10.3(d) and/or 10.3(e); MOL Licence, Section 10.3(c) and/or 10.3(d).



We encourage you to contact us prior to the date stipulated above to discuss our partnership under the Agreements and/or to propose a plan to cure Arene's breaches.

MPP reserves all of its rights under the Agreements and nothing in this letter should be construed as relieving Arene of its ongoing obligations thereunder.

Sincerely

Bryce Robinson

Associate Counsel Medicines Patent Pool